{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:22:23Z","timestamp":1767374543943,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"am","delay-in-days":171,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001130","name":"Gerber Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jbior.2020.100723","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T12:30:29Z","timestamp":1588681829000},"page":"100723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects"],"prefix":"10.1016","volume":"78","author":[{"given":"Suresh C.","family":"Jhanwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang Leon","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abul H.","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2020.100723_bib1","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib2","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jbior.2020.100723_bib3","first-page":"429","article-title":"ALK inhibitors in non-small cell lung cancer: crizotinib and beyond","volume":"12","author":"Awad","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.jbior.2020.100723_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nature10275","article-title":"A continuum model for tumour suppression","volume":"471","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2020.100723_bib5","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Acad Sci U S A"},{"key":"10.1016\/j.jbior.2020.100723_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jbior.2019.03.002","article-title":"Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals","volume":"72","author":"Candido","year":"2019","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2020.100723_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","article-title":"Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation","volume":"24","author":"Cheng","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jbior.2020.100723_bib9","first-page":"5410","article-title":"Genetic alterations of the p53 gene are a feature of malignant mesotheliomas","volume":"51","author":"Cote","year":"1991","journal-title":"Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2020.100723_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(01)90112-X","article-title":"Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia","volume":"38","author":"Druker","year":"2001","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.jbior.2020.100723_bib12","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-08-1306","article-title":"Novel therapeutic inhibitors of the c-Met signaling pathway in cancer","volume":"15","author":"Eder","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","article-title":"Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma","volume":"166","author":"Favoni","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbior.2020.100723_bib14","first-page":"13","article-title":"Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors","volume":"15","author":"Gerdes","year":"1995","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbior.2020.100723_bib15","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1158\/0008-5472.CAN-10-0409","article-title":"PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK\/ERK and mutant KRAS signaling","volume":"70","author":"Halilovic","year":"2010","journal-title":"Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2020.100723_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2020.100723_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molcel.2004.09.029","article-title":"An Rb-Skp 2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant","volume":"16","author":"Ji","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbior.2020.100723_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/cc.4.3.1535","article-title":"Using kinetic studies to uncover new Rb functions in inhibiting cell cycle progression","volume":"3","author":"Ji","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jbior.2020.100723_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Canc. Discov."},{"key":"10.1016\/j.jbior.2020.100723_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","article-title":"EGFR fusions as novel therapeutic targets in lung cancer","volume":"6","author":"Konduri","year":"2016","journal-title":"Canc. Discov."},{"key":"10.1016\/j.jbior.2020.100723_bib22","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib23","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-13-1591","article-title":"Beyond histology: translating tumor genotypes into clinically effective targeted therapies","volume":"20","author":"Meador","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-13-2062","article-title":"Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis","volume":"74","author":"Menges","year":"2014","journal-title":"Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ccr.2011.05.023","article-title":"Oncogene-induced mitotic stress: p53 and pRb get mad too","volume":"19","author":"Malumbres","year":"2011","journal-title":"Canc. Cell"},{"key":"10.1016\/j.jbior.2020.100723_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc3894","article-title":"Revisiting tissue specificity of germline cancer predisposing mutations","volume":"15","author":"Maris","year":"2015","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.jbior.2020.100723_bib27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 Cell cycle control and cancer","volume":"432","author":"Massague","year":"2004","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.jbior.2020.100723_bib28","article-title":"Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis","volume":"S2212\u20134926","author":"McCubrey","year":"2016","journal-title":"Adv Biol Regul. pii"},{"year":"2019","series-title":"Effects of Restoration of WT-TP53 Expression on Pancreatic Cancer Gene Expression and Sensitivity to Various Therapeutic and Tumorigenicity","author":"McCubrey","key":"10.1016\/j.jbior.2020.100723_bib29"},{"key":"10.1016\/j.jbior.2020.100723_bib30","article-title":"Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers","volume":"2","author":"Offin","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jbior.2020.100723_bib31","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib32","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jbior.2020.100723_bib33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jbior.2017.01.002","article-title":"Genomic instability and proliferation\/survival pathways in RB1-deficient malignancies (2017)","volume":"64","author":"Pappas","year":"2018","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2020.100723_bib34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature08629","article-title":"A small-cell lung cancer genome with complex signatures of tobacco exposure","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2020.100723_bib35","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jbior.2020.100723_bib36","first-page":"1544","article-title":"Histopathological, cytogenetic, and molecular characterization of renal cortical tumors","volume":"51","author":"Presti","year":"1991","journal-title":"Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2017.10.008","article-title":"Nuclear inositide signaling and cell cycle","volume":"67","author":"Ratti","year":"2018","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2020.100723_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.jbior.2020.100723_bib39","article-title":"Fhit and Wwox loss-associated genome instability: a genome caretaker one-two punch","volume":"S2212\u20134926","author":"Schrock","year":"2016","journal-title":"Adv Biol Regul. pii:"},{"key":"10.1016\/j.jbior.2020.100723_bib40","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jbior.2020.100723_bib41","article-title":"Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer","volume":"3","author":"Suzawa","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jbior.2020.100723_bib42","series-title":"Text Book of Pleural Diseases","first-page":"pp125","article-title":"Genetic alterations in mesothelioma pathogenesis","author":"Testa","year":"2008"},{"key":"10.1016\/j.jbior.2020.100723_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2020.100723_bib44","article-title":"Dissecting pathologies associated withg PTEN loss of function","author":"Wise","year":"2019","journal-title":"ABR"},{"key":"10.1016\/j.jbior.2020.100723_bib45","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1128\/MCB.25.6.2384-2394.2005","article-title":"The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression","volume":"25","author":"Xiao","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbior.2020.100723_bib46","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.cell.2009.03.051","article-title":"Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling","volume":"137","author":"Xu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2020.100723_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature13813","article-title":"Rb suppresses human cone precursor-derived retinoblastoma tumors","volume":"511","author":"Xu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2020.100723_bib48","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1158\/0008-5472.CAN-16-3299","article-title":"SKP2 activation by thyroid hormone receptor beta 2 bypasses Rb-dependent proliferation in Rb-deficient cells","volume":"77","author":"Xu","year":"2017","journal-title":"Canc. Res."},{"key":"10.1016\/j.jbior.2020.100723_bib49","article-title":"Protein kinase C1and WNT\/\u03b2-catenin signaling: alternative pathways to KRAS\/TRP53 driven lung adenocarcinoma","author":"Yin","year":"2019","journal-title":"ABR"},{"key":"10.1016\/j.jbior.2020.100723_bib50","first-page":"100656","article-title":"Oncogenic protein kinase C\u03b9 signaling mechanisms in lung cancer: implications for improved therapeutic strategies","author":"Yin","year":"2019","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jbior.2020.100723_bib51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1126\/science.1256930","article-title":"Intratumor heterogeneity in localized lung adenocarcinomas delineate multiregion sequencing","volume":"346","author":"Zhang","year":"2014","journal-title":"Science"}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492620300348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492620300348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:26:28Z","timestamp":1761949588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492620300348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":50,"alternative-id":["S2212492620300348"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2020.100723","relation":{},"ISSN":["2212-4926"],"issn-type":[{"type":"print","value":"2212-4926"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2020.100723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100723"}}